Key result
In patients with VTE and major bleeding, insertion of a vena cava filter was independently associated with a lower incidence of fatal bleeding (OR 0.10; 95% CI 0.01-0.79) and all-cause mortality.
Why the study?
What are the clinical outcomes and mortality rates in patients with VTE who develop major bleeding during the first three months of anticoagulant therapy?
Population
407 patients with symptomatic, objectively confirmed, acute venous thromboembolism who had major bleeding…
Design
Cohort
Follow-up
30 days after bleeding
Authors
Loading...
May support filter evaluation in VTE with major bleeding; leaves open causal confirmation in randomized trials.
Cohort (n=407)
What are the clinical outcomes and mortality rates in patients with VTE who develop major bleeding during the first three months of anticoagulant therapy?
Odds Ratio: 0.1 (95% CI 0.01–0.79)
Major bleeding during the first three months of VTE treatment is associated with an exceptionally high 30-day mortality of 33%, though vena cava filter insertion was associated with reduced mortality.
Nieto et al. (2008) conducted a cohort in Venous thromboembolism with major bleeding (n=407). Insertion of a vena cava filter vs. No vena cava filter was evaluated on Fatal bleeding (OR 0.10, 95% CI 0.01-0.79). In patients with VTE and major bleeding, insertion of a vena cava filter was independently associated with a lower incidence of fatal bleeding (OR 0.10; 95% CI 0.01-0.79) and all-cause mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: